MSK Department of Medicine
@mskdeptofmed.bsky.social
The official account of @mskcancercenter.bsky.social's Department of Medicine. Chair/Dept. Head: Deb Schrag
Out in @bmjmedicine.bsky.social: Dr. Corita Grudzen & team examined whether follow-up palliative care via outpatient visits or nurse-led phone calls led to better outcomes for seriously ill adults who recently visited the emergency department. @mskcancercenter.bsky.social
➡️ bit.ly/48bhFOx
➡️ bit.ly/48bhFOx
November 14, 2025 at 8:36 PM
Out in @bmjmedicine.bsky.social: Dr. Corita Grudzen & team examined whether follow-up palliative care via outpatient visits or nurse-led phone calls led to better outcomes for seriously ill adults who recently visited the emergency department. @mskcancercenter.bsky.social
➡️ bit.ly/48bhFOx
➡️ bit.ly/48bhFOx
#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social
➡️ bit.ly/3JncnWA
➡️ bit.ly/3JncnWA
October 21, 2025 at 3:28 PM
#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social
➡️ bit.ly/3JncnWA
➡️ bit.ly/3JncnWA
This morning at #ESMO25, William Tap gave a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/47h3DJG
Learn more: bit.ly/47h3DJG
October 20, 2025 at 1:19 PM
This morning at #ESMO25, William Tap gave a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/47h3DJG
Learn more: bit.ly/47h3DJG
At #ESMO25, join Dr. Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4nafnUa
Learn more: bit.ly/4nafnUa
October 19, 2025 at 12:30 PM
At #ESMO25, join Dr. Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4nafnUa
Learn more: bit.ly/4nafnUa
Happening NOW at #ESMO25: View Kenneth Yu's poster about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation.
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
October 19, 2025 at 10:00 AM
Happening NOW at #ESMO25: View Kenneth Yu's poster about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation.
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
@mskcancercenter.bsky.social
Learn more: bit.ly/3KZ0iHw
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
October 18, 2025 at 5:02 PM
At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
🗓️ October 19, 9:25 a.m. CEST
Learn more: bit.ly/4n5B8od
Happening tomorrow at #ESMO25: Helena Yu will share preliminary results from the ongoing phase 2b trial of zipalertinib in patients with non-small cell #lungcancer who have central nervous system #metastases. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W74yY3
Learn more: bit.ly/3W74yY3
October 18, 2025 at 4:03 PM
Happening tomorrow at #ESMO25: Helena Yu will share preliminary results from the ongoing phase 2b trial of zipalertinib in patients with non-small cell #lungcancer who have central nervous system #metastases. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W74yY3
Learn more: bit.ly/3W74yY3
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
October 18, 2025 at 3:02 PM
Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3WcyfH5
Learn more: bit.ly/3WcyfH5
Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social
Learn more: bit.ly/42JM3ws
Learn more: bit.ly/42JM3ws
October 17, 2025 at 6:30 PM
Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social
Learn more: bit.ly/42JM3ws
Learn more: bit.ly/42JM3ws
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
October 17, 2025 at 5:03 PM
Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/3W6rqqz
Learn more: bit.ly/3W6rqqz
Tomorrow at #ESMO25, Violaine Randrian will present a study investigating whether the mechanism of mismatch repair protein loss impacts outcomes for those with solid tumors treated with #immunotherapy. @mskcancercenter.bsky.social
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
October 17, 2025 at 3:04 PM
Tomorrow at #ESMO25, Violaine Randrian will present a study investigating whether the mechanism of mismatch repair protein loss impacts outcomes for those with solid tumors treated with #immunotherapy. @mskcancercenter.bsky.social
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
Learn more: bit.ly/4neLsu1
🗓️ October 18 | 11:10 a.m. CEST
Exciting research is ahead at #ESMO25! Tomorrow, Dr. Michael Foote will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4qrq3Rg
Learn more: bit.ly/4qrq3Rg
October 16, 2025 at 1:02 PM
Exciting research is ahead at #ESMO25! Tomorrow, Dr. Michael Foote will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social
Learn more: bit.ly/4qrq3Rg
Learn more: bit.ly/4qrq3Rg
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm
🗓️ Saturday, September 20 | 9:20 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
🗓️ Saturday, September 20 | 9:20 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
September 20, 2025 at 12:01 PM
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm
🗓️ Saturday, September 20 | 9:20 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
🗓️ Saturday, September 20 | 9:20 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm
🗓️ Friday, September 19 | 9:40 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social
🗓️ Friday, September 19 | 9:40 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social
September 19, 2025 at 12:03 PM
Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm
🗓️ Friday, September 19 | 9:40 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social
🗓️ Friday, September 19 | 9:40 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 18, 2025 at 6:02 PM
Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Thursday, September 18 | 4:40 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.
🗓️ Wednesday, September 17 | 12:14 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Wednesday, September 17 | 12:14 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 17, 2025 at 2:04 PM
At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.
🗓️ Wednesday, September 17 | 12:14 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Wednesday, September 17 | 12:14 p.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm
🗓️ Wednesday, September 17 | 11:10 a.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Wednesday, September 17 | 11:10 a.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
September 17, 2025 at 12:03 PM
MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm
🗓️ Wednesday, September 17 | 11:10 a.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
🗓️ Wednesday, September 17 | 11:10 a.m. EDT
@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social
Starting TODAY! Join @greatdebates.bsky.social
and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer.
@mskcancercenter.bsky.social #crcsm #GIcancer
See the full agenda 📖: bit.ly/48g13pf
and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer.
@mskcancercenter.bsky.social #crcsm #GIcancer
See the full agenda 📖: bit.ly/48g13pf
September 13, 2025 at 2:49 PM
Starting TODAY! Join @greatdebates.bsky.social
and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer.
@mskcancercenter.bsky.social #crcsm #GIcancer
See the full agenda 📖: bit.ly/48g13pf
and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer.
@mskcancercenter.bsky.social #crcsm #GIcancer
See the full agenda 📖: bit.ly/48g13pf
🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
September 12, 2025 at 1:07 PM
🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V
Tomorrow morning, #lungcancer expert Mark Kris will discuss clinicopathologic features of TP53/RB1-mutant squamous cell lung cancers at #WCLC25. #LCSM @iaslc.bsky.social @mskcancercenter.bsky.social
September 8 | 10:30 a.m.. CEST
➡️ bit.ly/41EZM7b
September 8 | 10:30 a.m.. CEST
➡️ bit.ly/41EZM7b
September 7, 2025 at 3:18 PM
Tomorrow morning, #lungcancer expert Mark Kris will discuss clinicopathologic features of TP53/RB1-mutant squamous cell lung cancers at #WCLC25. #LCSM @iaslc.bsky.social @mskcancercenter.bsky.social
September 8 | 10:30 a.m.. CEST
➡️ bit.ly/41EZM7b
September 8 | 10:30 a.m.. CEST
➡️ bit.ly/41EZM7b
Coming up at #WCLC25: @mskcancercenter.bsky.social's Helena Yu will highlight diagnostic and treatment opportunities for #leptomeningealdisease in oncogene-driven non-small cell #lungcancer. #LCSM @iaslc.bsky.social
September 7 | 3:53 p.m. CEST
➡️ bit.ly/4mOHBnV
September 7 | 3:53 p.m. CEST
➡️ bit.ly/4mOHBnV
September 7, 2025 at 1:00 PM
Coming up at #WCLC25: @mskcancercenter.bsky.social's Helena Yu will highlight diagnostic and treatment opportunities for #leptomeningealdisease in oncogene-driven non-small cell #lungcancer. #LCSM @iaslc.bsky.social
September 7 | 3:53 p.m. CEST
➡️ bit.ly/4mOHBnV
September 7 | 3:53 p.m. CEST
➡️ bit.ly/4mOHBnV
Don't miss an opportunity to learn from the Chief of the Thoracic Oncology Service at @mskcancercenter.bsky.social! At #WCLC25, Mark Awad will share lessons about work-life balance in high-stress medical careers. #LCSM @iaslc.bsky.social
September 7 | 1:45 p.m. CEST
➡️ bit.ly/3HTNpxr
September 7 | 1:45 p.m. CEST
➡️ bit.ly/3HTNpxr
September 7, 2025 at 10:45 AM
Don't miss an opportunity to learn from the Chief of the Thoracic Oncology Service at @mskcancercenter.bsky.social! At #WCLC25, Mark Awad will share lessons about work-life balance in high-stress medical careers. #LCSM @iaslc.bsky.social
September 7 | 1:45 p.m. CEST
➡️ bit.ly/3HTNpxr
September 7 | 1:45 p.m. CEST
➡️ bit.ly/3HTNpxr
Happening tomorrow at #WCLC25: @mskcancercenter.bsky.social's @charlesrudin.bsky.social will highlight future directions in small cell #lungcancer research. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social
September 6 | 10:30 a.m. CEST
➡️ bit.ly/3HJJmnp
September 6 | 10:30 a.m. CEST
➡️ bit.ly/3HJJmnp
September 5, 2025 at 4:54 PM
Happening tomorrow at #WCLC25: @mskcancercenter.bsky.social's @charlesrudin.bsky.social will highlight future directions in small cell #lungcancer research. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social
September 6 | 10:30 a.m. CEST
➡️ bit.ly/3HJJmnp
September 6 | 10:30 a.m. CEST
➡️ bit.ly/3HJJmnp
Results of a pilot study led by investigators at @mskcancercenter.bsky.social showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @markgeyermd.bsky.social
Learn more: bit.ly/4mFwo9q
Learn more: bit.ly/4mFwo9q
September 2, 2025 at 2:34 PM
Results of a pilot study led by investigators at @mskcancercenter.bsky.social showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @markgeyermd.bsky.social
Learn more: bit.ly/4mFwo9q
Learn more: bit.ly/4mFwo9q
Congrats to Rastko Rakočević of the Pulmonary Service on receiving a certificate of excellence for presenting a top abstract in a plenary session at #AABIP2025! He presented research on robotic-assisted #bronchoscopy for biopsy of primary #lungcancers. @mskcancercenter.bsky.social
August 29, 2025 at 6:37 PM
Congrats to Rastko Rakočević of the Pulmonary Service on receiving a certificate of excellence for presenting a top abstract in a plenary session at #AABIP2025! He presented research on robotic-assisted #bronchoscopy for biopsy of primary #lungcancers. @mskcancercenter.bsky.social